https://pharmadevicenews.com/can-beam-healthcare-and-simvuly-turn-same-day-specialist-advice-into-a-practical-national-care-model/ 2026-07-22T04:31:38+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Beam-Healthcare-and-Simvuly-target-referral-delays-with-same-day-eConsult-access-e1784694657524.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Beam-Healthcare-and-Simvuly-target-referral-delays-with-same-day-eConsult-access-e1784694657524.webp https://pharmadevicenews.com/can-one-hiv-pill-a-week-replace-daily-therapy-gilead-and-mercks-phase-3-data-raise-the-stakes/ 2026-07-22T05:26:56+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Gilead-and-Merck-once-weekly-HIV-pill-meets-Phase-3-noninferiority-goals-e1784697975297.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Gilead-and-Merck-once-weekly-HIV-pill-meets-Phase-3-noninferiority-goals-e1784697975297.webp https://pharmadevicenews.com/evonik-and-evitria-say-this-cho-kit-can-cut-biologics-troubleshooting-will-laboratories-make-the-switch/ 2026-07-22T05:32:21+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Evonik-partnership-with-evitria-expands-access-to-transient-CHO-expression-tools-e1784698297746.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Evonik-partnership-with-evitria-expands-access-to-transient-CHO-expression-tools-e1784698297746.webp https://pharmadevicenews.com/what-brukers-disqver-acquisition-means-for-sepsis-and-bloodstream-infection-testing/ 2026-07-22T05:36:51+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/DISQVER-joins-Bruker-as-regulatory-and-hospital-adoption-tests-come-into-focus-e1784698568503.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/DISQVER-joins-Bruker-as-regulatory-and-hospital-adoption-tests-come-into-focus-e1784698568503.webp https://pharmadevicenews.com/evox-therapeutics-advances-msh3-huntingtons-disease-programme-through-exmoor-pharma-transfer/ 2026-07-22T05:40:59+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/eXmoor-Pharma-and-Evox-build-manufacturing-foundation-for-MSH3-gene-editing-therapy-e1784698812509.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/eXmoor-Pharma-and-Evox-build-manufacturing-foundation-for-MSH3-gene-editing-therapy-e1784698812509.webp https://pharmadevicenews.com/can-cellares-automation-move-papillons-ppl-001-closer-to-a-friedreichs-ataxia-trial/ 2026-07-22T06:49:24+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Papillon-PPL-001-remains-preclinical-as-Cellares-takes-on-manufacturing-automation-e1784702919946.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Papillon-PPL-001-remains-preclinical-as-Cellares-takes-on-manufacturing-automation-e1784702919946.webp https://pharmadevicenews.com/why-vasomune-is-taking-its-av-001-vascular-leak-strategy-into-combat-casualty-medicine/ 2026-07-22T06:53:35+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Vasomune-takes-AV-001-vascular-leak-strategy-into-combat-casualty-medicine-e1784703177372.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Vasomune-takes-AV-001-vascular-leak-strategy-into-combat-casualty-medicine-e1784703177372.webp https://pharmadevicenews.com/arcus-biosciences-august-5-call-looks-routine-but-its-biggest-pipeline-test-is-approaching/ 2026-07-22T06:58:11+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Arcus-Biosciences-Q2-call-could-clarify-its-post-domvanalimab-development-strategy-e1784703447940.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Arcus-Biosciences-Q2-call-could-clarify-its-post-domvanalimab-development-strategy-e1784703447940.webp https://pharmadevicenews.com/dd-pharmatechs-mash-candidate-gains-credibility-as-phase-2-findings-enter-peer-review/ 2026-07-22T07:02:22+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/DD-Pharmatech-publishes-zabopegdutide-Phase-2-MASLD-and-MASH-data-in-The-Lancet.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/DD-Pharmatech-publishes-zabopegdutide-Phase-2-MASLD-and-MASH-data-in-The-Lancet.webp https://pharmadevicenews.com/demetra-wants-to-move-beyond-implants-can-masmec-biomed-help-build-its-surgical-technology-ecosystem/ 2026-07-22T11:35:13+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Demetra-and-Masmec-Biomed-form-strategic-collaboration-for-surgical-AI-and-navigation-e1784720075304.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Demetra-and-Masmec-Biomed-form-strategic-collaboration-for-surgical-AI-and-navigation-e1784720075304.webp https://pharmadevicenews.com/signatera-detected-90-of-recurrences-versus-55-for-amerk-is-merkel-cell-surveillance-about-to-change/ 2026-07-22T11:41:36+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Natera-expands-Signatera-evidence-with-head-to-head-Merkel-cell-carcinoma-study-e1784720429133.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Natera-expands-Signatera-evidence-with-head-to-head-Merkel-cell-carcinoma-study-e1784720429133.webp https://pharmadevicenews.com/how-science-corporations-prima-system-restores-prosthetic-central-vision-in-advanced-amd/ 2026-07-22T11:47:33+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/PRIMA-retinal-implant-targets-central-vision-loss-caused-by-geographic-atrophy-e1784720743771.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/PRIMA-retinal-implant-targets-central-vision-loss-caused-by-geographic-atrophy-e1784720743771.webp https://pharmadevicenews.com/summit-therapeutics-nears-fda-decision-with-stronger-ivonescimab-survival-signal/ 2026-07-22T11:51:22+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Summit-Therapeutics-stock-rises-as-ivonescimab-survival-trend-improves-e1784721040714.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Summit-Therapeutics-stock-rises-as-ivonescimab-survival-trend-improves-e1784721040714.webp https://pharmadevicenews.com/johnson-johnson-has-entered-soft-tissue-robotics-but-can-ottava-loosen-da-vincis-grip/ 2026-07-22T13:28:13+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Johnson-Johnson-opens-new-surgical-robotics-front-with-FDA-authorized-Ottava-scaled-e1784726842874.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Johnson-Johnson-opens-new-surgical-robotics-front-with-FDA-authorized-Ottava-scaled-e1784726842874.webp https://pharmadevicenews.com/can-bostongenes-ai-reveal-which-gastrointestinal-cancer-patients-will-benefit-from-ici-pdt-therapy/ 2026-07-22T16:45:32+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/BostonGene-AI-platform-joins-Phase-II-NOBEL-ioPDT-gastrointestinal-cancer-trial-e1784738692780.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/BostonGene-AI-platform-joins-Phase-II-NOBEL-ioPDT-gastrointestinal-cancer-trial-e1784738692780.webp https://pharmadevicenews.com/conmeds-airseal-gains-a-crucial-da-vinci-5-fit-but-will-hospitals-change-their-robotic-workflow/ 2026-07-22T16:52:59+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/CONMED-broadens-AirSeal-access-as-hospitals-transition-to-the-da-Vinci-5-platform-e1784739137265.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/CONMED-broadens-AirSeal-access-as-hospitals-transition-to-the-da-Vinci-5-platform-e1784739137265.webp https://pharmadevicenews.com/why-royalty-pharma-is-betting-up-to-425m-on-neurimmunes-phase-3-heart-drug/ 2026-07-22T16:57:06+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Royalty-Pharma-expands-ATTR-CM-exposure-with-Phase-3-cliramitug-deal-e1784739380255.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Royalty-Pharma-expands-ATTR-CM-exposure-with-Phase-3-cliramitug-deal-e1784739380255.webp https://pharmadevicenews.com/cizzle-bio-launches-ciz1b-lung-cancer-blood-test-in-limited-texas-commercial-rollout/ 2026-07-22T17:27:32+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Cizzle-Bio-starts-limited-U.S.-rollout-of-CIZ1B-test-for-early-lung-cancer-assessment-e1784741201220.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Cizzle-Bio-starts-limited-U.S.-rollout-of-CIZ1B-test-for-early-lung-cancer-assessment-e1784741201220.webp https://pharmadevicenews.com/curis-expands-emavusertib-pcnsl-response-pool-as-takeaim-cll-enrolment-accelerates/ 2026-07-22T17:32:59+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Curis-reports-updated-emavusertib-response-data-in-relapsed-PCNSL-e1784741541664.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Curis-reports-updated-emavusertib-response-data-in-relapsed-PCNSL-e1784741541664.webp https://pharmadevicenews.com/mentari-just-raised-another-200m-for-migraine-but-can-its-pacap-antibodies-clear-the-clinical-test/ 2026-07-22T17:37:43+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Mentari-Therapeutics-funding-extends-PACAP-migraine-runway-into-2029-e1784741813528.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Mentari-Therapeutics-funding-extends-PACAP-migraine-runway-into-2029-e1784741813528.webp https://pharmadevicenews.com/could-ultromics-echogo-improve-early-detection-of-heart-failure-with-preserved-ejection-fraction/ 2026-07-22T17:42:39+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Ultromics-EchoGo-gains-third-party-assessment-of-clinical-and-economic-HFpEF-impact-e1784742121333.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Ultromics-EchoGo-gains-third-party-assessment-of-clinical-and-economic-HFpEF-impact-e1784742121333.webp https://pharmadevicenews.com/why-repligens-1-5bn-biolife-solutions-deal-could-reshape-cell-therapy-manufacturing/ 2026-07-22T17:53:02+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Cell-therapy-e1784742716750.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Cell-therapy-e1784742716750.webp https://pharmadevicenews.com/what-will-marquis-mds-boca-raton-concierge-medicine-membership-include/ 2026-07-23T03:42:20+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Marquis-MD-adds-pediatrics-and-advanced-diagnostics-to-concierge-care-model-e1784778100478.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Marquis-MD-adds-pediatrics-and-advanced-diagnostics-to-concierge-care-model-e1784778100478.webp https://pharmadevicenews.com/can-topgum-turn-brain-and-eye-health-into-the-next-major-gummy-growth-category/ 2026-07-23T03:46:05+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/TopGum-eye-health-gummy-combines-10-mg-lutein-with-2-mg-zeaxanthin-e1784778330175.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/TopGum-eye-health-gummy-combines-10-mg-lutein-with-2-mg-zeaxanthin-e1784778330175.webp https://pharmadevicenews.com/can-tikva-allocells-8m-bet-solve-the-persistence-problem-holding-back-off-the-shelf-car-t/ 2026-07-23T03:51:13+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Tikva-Allocell-targets-host-immune-rejection-with-engineered-EBV-specific-T-cells-e1784778631665.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Tikva-Allocell-targets-host-immune-rejection-with-engineered-EBV-specific-T-cells-e1784778631665.webp https://pharmadevicenews.com/caredx-shares-have-doubled-in-2026-will-july-30-earnings-support-the-surge/ 2026-07-23T04:07:43+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/CareDx-prepares-Q2-results-after-Eurobio-divestiture-and-Naveris-acquisition-e1784779621972.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/CareDx-prepares-Q2-results-after-Eurobio-divestiture-and-Naveris-acquisition-e1784779621972.webp https://pharmadevicenews.com/shasta-3-and-shasta-4-results-support-arrowhead-pharmaceuticals-planned-plozasiran-fda-filing/ 2026-07-23T04:11:49+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Arrowhead-Pharmaceuticals-stock-jumps-after-positive-Phase-3-plozasiran-trial-results-e1784779870509.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Arrowhead-Pharmaceuticals-stock-jumps-after-positive-Phase-3-plozasiran-trial-results-e1784779870509.webp https://pharmadevicenews.com/zai-labs-august-6-earnings-could-reveal-whether-its-2026-commercial-reset-is-starting-to-work/ 2026-07-23T04:15:42+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Zai-Lab-stock-steadies-before-Q2-results-as-investors-assess-commercial-execution-e1784780100594.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Zai-Lab-stock-steadies-before-Q2-results-as-investors-assess-commercial-execution-e1784780100594.webp https://pharmadevicenews.com/affinia-therapeutics-advances-aftx-201-gene-therapy-for-bag3-dilated-cardiomyopathy/ 2026-07-23T04:19:42+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Affinia-Therapeutics-gains-FDA-orphan-status-for-AFTX-201-in-BAG3-cardiomyopathy-e1784780340721.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Affinia-Therapeutics-gains-FDA-orphan-status-for-AFTX-201-in-BAG3-cardiomyopathy-e1784780340721.webp https://pharmadevicenews.com/corcept-therapeutics-sets-july-29-q2-call-as-lifyorli-launch-and-relacorilant-review-take-centre-stage/ 2026-07-23T05:10:46+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Corcept-Therapeutics-Q2-results-to-offer-first-commercial-readout-on-Lifyorli-launch-e1784783405608.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Corcept-Therapeutics-Q2-results-to-offer-first-commercial-readout-on-Lifyorli-launch-e1784783405608.webp https://pharmadevicenews.com/verastem-has-entered-the-kras-g12d-lung-cancer-race-but-can-vs-7375-close-the-evidence-gap/ 2026-07-23T05:13:57+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Verastem-begins-TARGET-D-202-Phase-2-trial-of-VS-7375-in-KRAS-G12D-NSCLC-e1784783595565.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Verastem-begins-TARGET-D-202-Phase-2-trial-of-VS-7375-in-KRAS-G12D-NSCLC-e1784783595565.webp https://pharmadevicenews.com/can-cosaras-30-minute-pcr-platform-close-indias-tuberculosis-testing-gap-the-decisive-studies-have-begun/ 2026-07-23T07:07:47+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/CoSara-begins-India-clinical-studies-of-Co-Diagnostics-rapid-tuberculosis-PCR-test-e1784790423320.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/CoSara-begins-India-clinical-studies-of-Co-Diagnostics-rapid-tuberculosis-PCR-test-e1784790423320.webp https://pharmadevicenews.com/can-eurofins-viracors-bkv-insight-panel-solve-a-dangerous-kidney-transplant-monitoring-blind-spot/ 2026-07-23T07:11:42+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Eurofins-Viracor-commercialises-BK-virus-specific-CD4-and-CD8-T-cell-monitoring-panel-e1784790660788.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Eurofins-Viracor-commercialises-BK-virus-specific-CD4-and-CD8-T-cell-monitoring-panel-e1784790660788.webp https://pharmadevicenews.com/europes-immuno-oncology-pipeline-has-a-translation-problem-can-sitcs-lausanne-summit-fix-it/ 2026-07-23T07:15:28+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/SITC-and-Swiss-Biotech-Association-strengthen-Europes-immuno-oncology-development-network-e1784790880314.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/SITC-and-Swiss-Biotech-Association-strengthen-Europes-immuno-oncology-development-network-e1784790880314.webp https://pharmadevicenews.com/can-amidas-saraswati-end-the-annual-hedis-scramble-for-health-plans/ 2026-07-23T07:18:48+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Amida-launches-NCQA-certified-HEDIS-measurement-platform-Saraswati-e1784791093672.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Amida-launches-NCQA-certified-HEDIS-measurement-platform-Saraswati-e1784791093672.webp https://pharmadevicenews.com/ciprocopan-china-approval-gives-pnh-patients-a-new-once-daily-oral-factor-b-treatment-option/ 2026-07-23T16:06:16+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Laboratory-researchers-e1784822111116.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Laboratory-researchers-e1784822111116.webp https://pharmadevicenews.com/inhibikase-therapeutics-gains-fda-orphan-status-for-ikt-001-as-pivotal-pah-trial-advances/ 2026-07-23T18:24:59+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Cardiopulmonary-data-e1784830900461.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Cardiopulmonary-data-e1784830900461.webp https://pharmadevicenews.com/incannex-healthcare-begins-dreamzz-screening-to-refine-ihl-42x-dosing-before-phase-3-sleep-apnea-trial/ 2026-07-23T19:59:10+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/sleep-study-e1784836706982.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/sleep-study-e1784836706982.webp https://pharmadevicenews.com/scancell-secures-path-to-89m-financing-through-neuphoria-therapeutics-merger/ 2026-07-23T21:55:35+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Clinical-teams-review-trial-data-e1784843420805.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Clinical-teams-review-trial-data-e1784843420805.webp https://pharmadevicenews.com/can-a-bitter-hop-supplement-protect-muscle-during-weight-loss-calocurb-trial-offers-an-early-answer/ 2026-07-24T05:07:44+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Calocurb-clinical-trial-finds-weight-and-fat-reduction-without-measured-muscle-loss-e1784869602343.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Calocurb-clinical-trial-finds-weight-and-fat-reduction-without-measured-muscle-loss-e1784869602343.webp https://pharmadevicenews.com/align-technology-expands-invisalign-digital-platform-with-ai-assisted-diagnostics-and-3d-treatment-planning/ 2026-07-24T05:30:56+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Align-Technology-deepens-digital-dentistry-strategy-ahead-of-second-quarter-results-e1784870958798.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Align-Technology-deepens-digital-dentistry-strategy-ahead-of-second-quarter-results-e1784870958798.webp https://pharmadevicenews.com/what-ge-healthcares-cfo-transition-means-before-its-july-29-earnings-report/ 2026-07-24T05:34:34+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/George-Newcomb-takes-interim-CFO-role-as-GE-HealthCare-begins-permanent-search-e1784871234364.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/George-Newcomb-takes-interim-CFO-role-as-GE-HealthCare-begins-permanent-search-e1784871234364.webp https://pharmadevicenews.com/summit-therapeutics-has-690-7m-but-one-november-fda-decision-now-towers-over-everything/ 2026-07-24T05:38:32+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Summit-Therapeutics-increases-ivonescimab-research-spending-ahead-of-November-FDA-decision-e1784871472856.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Summit-Therapeutics-increases-ivonescimab-research-spending-ahead-of-November-FDA-decision-e1784871472856.webp https://pharmadevicenews.com/avacta-previews-ava6103-pharmacokinetic-data-as-sustained-release-cancer-drug-faces-first-human-test/ 2026-07-24T07:06:09+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Avactas-next-cancer-data-could-validate-far-more-than-one-experimental-drug-e1784876716933.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Avactas-next-cancer-data-could-validate-far-more-than-one-experimental-drug-e1784876716933.webp https://pharmadevicenews.com/mindwalk-says-ai-models-are-replaceable-can-reefiq-make-biological-context-the-real-drug-discovery-moat/ 2026-07-24T07:13:46+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/MindWalk-tests-ReefIQ-commercial-potential-after-reporting-46-fiscal-2026-revenue-growth-e1784877182108.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/MindWalk-tests-ReefIQ-commercial-potential-after-reporting-46-fiscal-2026-revenue-growth-e1784877182108.webp https://pharmadevicenews.com/genmab-and-abbvie-clarify-epcore-dlbcl-1-missed-sole-us-overall-survival-endpoint/ 2026-07-24T07:18:33+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Genmab-and-AbbVie-clarify-US-endpoint-failure-in-EPCORE-DLBCL-1-trial-e1784877469635.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Genmab-and-AbbVie-clarify-US-endpoint-failure-in-EPCORE-DLBCL-1-trial-e1784877469635.webp https://pharmadevicenews.com/can-onelegacys-organox-perfusion-hub-turn-more-donor-livers-into-viable-transplants/ 2026-07-24T07:22:49+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/OrganOx-metra-partnership-tests-centralized-liver-perfusion-model-in-California-e1784877730272.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/OrganOx-metra-partnership-tests-centralized-liver-perfusion-model-in-California-e1784877730272.webp https://pharmadevicenews.com/biobuilder-secures-nearly-1m-massachusetts-grant-for-ai-guided-biotech-training/ 2026-07-24T07:27:14+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/BioBuilder-pilot-could-bring-AI-supported-biotech-instruction-to-70000-students-annually-e1784877993349.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/BioBuilder-pilot-could-bring-AI-supported-biotech-instruction-to-70000-students-annually-e1784877993349.webp https://pharmadevicenews.com/can-thyora-therapeutics-turn-a-strained-four-carbon-ring-into-safer-covalent-cancer-drugs/ 2026-07-24T10:27:27+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Thyora-Therapeutics-licenses-Moffitt-Cancer-Center-covalent-drug-technologies-e1784888807278.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Thyora-Therapeutics-licenses-Moffitt-Cancer-Center-covalent-drug-technologies-e1784888807278.webp https://pharmadevicenews.com/bayer-backed-self-care-research-highlights-referral-affordability-and-health-literacy-gaps/ 2026-07-24T10:31:23+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Bayer-Consumer-Health-research-links-supported-self-care-to-more-sustainable-healthcare-systems-e1784889036500.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Bayer-Consumer-Health-research-links-supported-self-care-to-more-sustainable-healthcare-systems-e1784889036500.webp https://pharmadevicenews.com/laminar-pharma-has-finished-patient-follow-up-now-one-survival-result-will-decide-lam561s-future/ 2026-07-24T10:36:27+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Laminar-Pharma-closes-active-monitoring-phase-of-144-patient-LAM561-clinical-trial-e1784889343718.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Laminar-Pharma-closes-active-monitoring-phase-of-144-patient-LAM561-clinical-trial-e1784889343718.webp https://pharmadevicenews.com/what-does-arkbios-ak0406-dosing-milestone-mean-for-long-acting-influenza-prevention/ 2026-07-24T10:40:16+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/ArkBio-moves-AK0406-into-six-month-safety-and-pharmacokinetic-follow-up-e1784889580706.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/ArkBio-moves-AK0406-into-six-month-safety-and-pharmacokinetic-follow-up-e1784889580706.webp https://pharmadevicenews.com/velmeni-just-cleared-a-major-dental-ai-hurdle-but-can-its-3d-cbct-platform-win-over-clinicians/ 2026-07-24T12:15:46+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Velmeni-expands-dental-AI-platform-with-FDA-cleared-3D-CBCT-imaging-software.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Velmeni-expands-dental-AI-platform-with-FDA-cleared-3D-CBCT-imaging-software.webp https://pharmadevicenews.com/lilac-biosciences-and-soin-neuroscience-publish-rna-biomarker-review-for-neuropathic-pain/ 2026-07-24T12:20:35+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Lilac-Biosciences-explores-RNA-based-pain-testing-with-Soin-Neuroscience-e1784895584806.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Lilac-Biosciences-explores-RNA-based-pain-testing-with-Soin-Neuroscience-e1784895584806.webp https://pharmadevicenews.com/what-regenative-labs-117-patient-protext-study-reveals-about-chronic-paraspinal-degeneration/ 2026-07-24T12:27:31+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Regenative-Labs-expands-ProText-evidence-as-FDA-regulatory-questions-remain-unresolved-e1784895986468.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Regenative-Labs-expands-ProText-evidence-as-FDA-regulatory-questions-remain-unresolved-e1784895986468.webp https://pharmadevicenews.com/harbour-biomeds-revenue-is-climbing-but-one-profit-number-complicates-the-growth-story/ 2026-07-24T12:31:55+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Harbour-BioMed-shares-face-new-test-after-seventh-profitable-half-year-e1784896258932.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Harbour-BioMed-shares-face-new-test-after-seventh-profitable-half-year-e1784896258932.webp https://pharmadevicenews.com/can-nadclinic-and-gcls-turn-longevity-medicines-training-gap-into-a-clinical-standard/ 2026-07-24T13:49:37+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/NADclinic-and-GCLS-build-education-pathway-for-preventive-longevity-medicine-e1784900936317.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/NADclinic-and-GCLS-build-education-pathway-for-preventive-longevity-medicine-e1784900936317.webp https://pharmadevicenews.com/why-alcon-and-aravinds-60-trainee-retina-surgery-hub-could-matter-far-beyond-coimbatore/ 2026-07-24T13:54:07+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Aravind-Eye-Care-System-and-Alcon-open-global-retina-surgery-training-centre-in-Coimbatore-e1784901204737.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Aravind-Eye-Care-System-and-Alcon-open-global-retina-surgery-training-centre-in-Coimbatore-e1784901204737.webp https://pharmadevicenews.com/why-par-healths-first-generic-janumet-xr-launch-could-trigger-a-rapid-u-s-pricing-reset/ 2026-07-24T13:59:28+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Par-Health-commercialises-approved-Janumet-XR-generic-after-patent-settlement-window-e1784901527496.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Par-Health-commercialises-approved-Janumet-XR-generic-after-patent-settlement-window-e1784901527496.webp https://pharmadevicenews.com/roches-new-vaginitis-pcr-test-is-fda-cleared-but-the-real-commercial-test-starts-inside-laboratories/ 2026-07-24T14:35:58+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/FDA-clears-Roche-cobas-BV-CV-PCR-assay-for-symptomatic-vaginitis-diagnosis-e1784903720439.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/FDA-clears-Roche-cobas-BV-CV-PCR-assay-for-symptomatic-vaginitis-diagnosis-e1784903720439.webp https://pharmadevicenews.com/mannkind-corporation-wins-fda-approval-for-10-second-furoscix-readyflow-furosemide-autoinjector/ 2026-07-24T15:51:19+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/At-home-autoinjector-e1784907964855.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/At-home-autoinjector-e1784907964855.webp https://pharmadevicenews.com/what-the-apollo-hospitals-and-precisio-biotix-lysin-partnership-means-for-indias-amr-crisis/ 2026-07-24T16:36:54+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Precisio-Biotix-gains-Apollo-Hospitals-network-for-clinical-validation-of-lysin-therapies-e1784910948859.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Precisio-Biotix-gains-Apollo-Hospitals-network-for-clinical-validation-of-lysin-therapies-e1784910948859.webp https://pharmadevicenews.com/gileads-trodelvy-cleared-a-key-eu-hurdle-but-can-it-really-replace-chemotherapy-in-first-line-tnbc/ 2026-07-24T17:51:53+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Gilead-moves-closer-to-EU-approval-for-Trodelvy-and-Keytruda-in-metastatic-TNBC-e1784915457620.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Gilead-moves-closer-to-EU-approval-for-Trodelvy-and-Keytruda-in-metastatic-TNBC-e1784915457620.webp https://pharmadevicenews.com/merck-is-licensing-alimatravir-before-phase-3-ends-can-a-monthly-hiv-pill-beat-the-access-clock/ 2026-07-24T17:55:11+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Merck-moves-early-on-HIV-prevention-access-as-alimatravir-trials-continue-e1784915670178.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Merck-moves-early-on-HIV-prevention-access-as-alimatravir-trials-continue-e1784915670178.webp https://pharmadevicenews.com/minoryx-therapeutics-secures-exceptional-circumstances-chmp-recommendation-for-leriglitazone/ 2026-07-25T00:27:16+00:00 https://pharmadevicenews.com/wp-content/uploads/2026/07/Neurology-consultation-e1784938704166.webp https://pharmadevicenews.com/wp-content/uploads/2026/07/Neurology-consultation-e1784938704166.webp